Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue JY, Gatto S, Fernandez-Banet J, Pavlicek A, Velastegui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF, Cassidy DP, Marx MA, Rybkin II, Johnson ML, Ou SI, Lito P, Papadopoulos KP, Janne PA, Olson P, Christensen JG.

Cancer Discov. 2019 Oct 28. pii: CD-19-1167. doi: 10.1158/2159-8290.CD-19-1167. [Epub ahead of print]

PMID:
31658955
2.

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.

Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, McCormick F.

Clin Cancer Res. 2019 Sep 12. doi: 10.1158/1078-0432.CCR-18-2779. [Epub ahead of print]

PMID:
31515463
3.

A treatment strategy for KRAS-driven tumors.

Mai TT, Lito P.

Nat Med. 2018 Jul;24(7):902-904. doi: 10.1038/s41591-018-0111-x. No abstract available.

PMID:
29988139
4.

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.

Arbour KC, Jordan E, Kim HR, Dienstag J, Yu HA, Sanchez-Vega F, Lito P, Berger M, Solit DB, Hellmann M, Kris MG, Rudin CM, Ni A, Arcila M, Ladanyi M, Riely GJ.

Clin Cancer Res. 2018 Jan 15;24(2):334-340. doi: 10.1158/1078-0432.CCR-17-1841. Epub 2017 Oct 31.

5.

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P.

Nat Med. 2017 Aug;23(8):929-937. doi: 10.1038/nm.4369. Epub 2017 Jul 17.

6.

Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.

Xue Y, Lito P.

Clin Cancer Res. 2017 Mar 15;23(6):1365-1367. doi: 10.1158/1078-0432.CCR-16-2576. Epub 2016 Dec 6.

7.

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.

Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC.

Clin Lung Cancer. 2016 Sep;17(5):e121-e129. doi: 10.1016/j.cllc.2016.01.003. Epub 2016 Jan 21.

8.

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.

Lito P, Solomon M, Li LS, Hansen R, Rosen N.

Science. 2016 Feb 5;351(6273):604-8. doi: 10.1126/science.aad6204. Epub 2016 Jan 14.

9.

Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O.

Sci Transl Med. 2014 May 28;6(238):238ra71. doi: 10.1126/scitranslmed.3008004.

10.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N.

Cancer Cell. 2014 May 12;25(5):697-710. doi: 10.1016/j.ccr.2014.03.011. Epub 2014 Apr 17.

11.

Tumor adaptation and resistance to RAF inhibitors.

Lito P, Rosen N, Solit DB.

Nat Med. 2013 Nov;19(11):1401-9. doi: 10.1038/nm.3392. Review.

PMID:
24202393
12.

Universal model for accurate calculation of tracer diffusion coefficients in gas, liquid and supercritical systems.

Lito PF, Magalhães AL, Gomes JR, Silva CM.

J Chromatogr A. 2013 May 17;1290:1-26. doi: 10.1016/j.chroma.2013.03.049. Epub 2013 Mar 27.

PMID:
23601290
13.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N.

Cancer Cell. 2012 Nov 13;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009.

14.

Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series.

Lito P, Pantanowitz L, Marotti J, Aboulafia DM, Campbell V, Bower M, Dezube BJ.

Am J Med Sci. 2009 Jan;337(1):1-4. doi: 10.1097/MAJ.0b013e31817d1cb7.

PMID:
19155751
15.

Sprouty 2 regulates DNA damage-induced apoptosis in Ras-transformed human fibroblasts.

Lito P, Mets BD, Appledorn DM, Maher VM, McCormick JJ.

J Biol Chem. 2009 Jan 9;284(2):848-54. doi: 10.1074/jbc.M808045200. Epub 2008 Nov 13.

16.

Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts.

Lito P, Mets BD, Kleff S, O'Reilly S, Maher VM, McCormick JJ.

J Biol Chem. 2008 Jan 25;283(4):2002-9. Epub 2007 Nov 28.

Supplemental Content

Support Center